Abstract
The challenge in developing an anti-cocaine vaccine is that cocaine is a small molecule, invisible to the immune system. Leveraging the knowledge that adenovirus (Ad) capsid proteins are highly immunogenic in humans, we hypothesized that linking a cocaine hapten to Ad capsid proteins would elicit high-affinity, high-titer antibodies against cocaine, sufficient to sequester systemically administered cocaine and prevent access to the brain, thus suppressing cocaine-induced behaviors. Based on these concepts, we developed dAd5GNE, a disrupted E1-E3- serotype 5 Ad with GNE, a stable cocaine analog, covalently linked to the Ad capsid proteins. In pre-clinical studies, dAd5GNE evoked persistent, high titer, high affinity IgG anti-cocaine antibodies, and was highly effective in blocking cocaine-induced hyperactivity and cocaine self-administration behavior in rats. Future studies will be designed to expand the efficacy studies, carry out relevant toxicology studies, and test dAd5GNE in human cocaine addicts.
Keywords: dAd5GNE, Cocaine, Addiction, Adenovirus, Vaccine, Anti-coccaine antibody, passive immunity, keyhole limpet hemocyanin, EDC, E1-E3-, Sensory nerve action potential, Palmitoylethanolamide, Laser evoked potential
CNS & Neurological Disorders - Drug Targets
Title: Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus
Volume: 10 Issue: 8
Author(s): George Koob, Martin J. Hicks, Sunmee Wee, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminksy, Amira Moreno, Kim D. Janda and Ronald G. Crystal
Affiliation:
Keywords: dAd5GNE, Cocaine, Addiction, Adenovirus, Vaccine, Anti-coccaine antibody, passive immunity, keyhole limpet hemocyanin, EDC, E1-E3-, Sensory nerve action potential, Palmitoylethanolamide, Laser evoked potential
Abstract: The challenge in developing an anti-cocaine vaccine is that cocaine is a small molecule, invisible to the immune system. Leveraging the knowledge that adenovirus (Ad) capsid proteins are highly immunogenic in humans, we hypothesized that linking a cocaine hapten to Ad capsid proteins would elicit high-affinity, high-titer antibodies against cocaine, sufficient to sequester systemically administered cocaine and prevent access to the brain, thus suppressing cocaine-induced behaviors. Based on these concepts, we developed dAd5GNE, a disrupted E1-E3- serotype 5 Ad with GNE, a stable cocaine analog, covalently linked to the Ad capsid proteins. In pre-clinical studies, dAd5GNE evoked persistent, high titer, high affinity IgG anti-cocaine antibodies, and was highly effective in blocking cocaine-induced hyperactivity and cocaine self-administration behavior in rats. Future studies will be designed to expand the efficacy studies, carry out relevant toxicology studies, and test dAd5GNE in human cocaine addicts.
Export Options
About this article
Cite this article as:
Koob George, J. Hicks Martin, Wee Sunmee, B. Rosenberg Jonathan, P. De Bishnu, M. Kaminksy Stephen, Moreno Amira, D. Janda Kim and G. Crystal Ronald, Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219334
DOI https://dx.doi.org/10.2174/187152711799219334 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of School-Based Physical Activity Interventions on Cognition and Academic Achievement: A Systematic Review
CNS & Neurological Disorders - Drug Targets Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry Immune Responses to AAV in Clinical Trials
Current Gene Therapy Environmentally Friendly Suzuki Aryl-Aryl Cross-Coupling Reaction
Current Organic Chemistry Depressed or Demented: Common CNS Drug Targets? !
Current Drug Targets - CNS & Neurological Disorders The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds Patent Selections
Recent Patents on Biotechnology Structure, Function and Interactions of Tau: Particular Focus on Potential Drug Targets for the Treatment of Tauopathies
CNS & Neurological Disorders - Drug Targets Possible Role of Hydroxylated Metabolites of Tacrine in Drug Toxicity and Therapy of Alzheimers Disease
Current Drug Metabolism Neural Stem Cells: From Neurobiology to Clinical Applications
Current Pharmaceutical Biotechnology Microbiota and Alcohol Use Disorder: Are Psychobiotics a Novel Therapeutic Strategy?
Current Pharmaceutical Design Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology PON1 Hypermethylation and PON3 Hypomethylation are Associated with Risk of Cerebral Infarction
Current Neurovascular Research Meet Our Editorial Board Member
The Natural Products Journal Farewell Note
Recent Patents on CNS Drug Discovery (Discontinued) Health Economic Modelling in Stratified Medicine - Example Depression
Current Pharmacogenomics and Personalized Medicine In Vitro Inhibition Of Three Different Drugs Used In Rheumatoid Arthritis Treatment On Human Serum Paraoxanase 1 Enzyme Activity
Protein & Peptide Letters Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets